Get the Stockscreener App
3.82
13.35%
0.45
After Hours:
3.85
0.03
+0.79%
Pds Biotechnology Corporation stock is traded at $3.82, with a volume of 1.42M.
It is up +13.35% in the last 24 hours and up +19.37% over the past month.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
See More
Previous Close:
$3.37
Open:
$3.5
24h Volume:
1.42M
Relative Volume:
3.70
Market Cap:
$138.81M
Revenue:
-
Net Income/Loss:
$-42.94M
P/E Ratio:
-2.358
EPS:
-1.62
Net Cash Flow:
$-33.64M
1W Performance:
+21.66%
1M Performance:
+19.37%
6M Performance:
-3.54%
1Y Performance:
-24.36%
1-Day Range:
$3.475
$3.85
1-Week Range:
$3.03
$3.85
52-Week Range:
$2.53
$6.85
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Name
Pds Biotechnology Corporation
Sector
Industry
Phone
800-208-3343
Address
303A COLLEGE ROAD EAST, PRINCETON
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-01-22 | Initiated | B. Riley Securities | Buy |
| Jun-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-27-20 | Initiated | Alliance Global Partners | Buy |
| Mar-09-20 | Initiated | Noble Capital Markets | Outperform |
| Oct-24-19 | Initiated | Chardan Capital Markets | Buy |
View All
Pds Biotechnology Corporation Stock (PDSB) Latest News
PDSB’s current quarter earnings: What analysts forecast? - US Post News
Three North Jersey startup tech firms get aid through state program - NorthJersey.com
Three North Jersey startup tech firms get state financing for R&D and salaries - Daily Record
PDS Biotechnology: Continuing The Holding Pattern (NASDAQ:PDSB) - Seeking Alpha
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Reaffirmed by HC Wainwright - MarketBeat
PDS: Updated Results, VERSATILE-002 Phase 2 Trial - ShareCast
PDS Biotech Advances with Promising Versamune® HPV Trial Results - TipRanks
PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 - StockTitan
PDS Biotechnology Co. (NASDAQ:PDSB) Receives Average Rating of "Buy" from Analysts - MarketBeat
PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of “Buy” by Brokerages - Defense World
Aneurysmal Subarachnoid Hemorrhage Drugs Market 95115.59mn Size, Spotlight on Future Potentials (2024-2034) - Talented India
PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024 - StockTitan
PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Cervical Cancer Clinical Trials 2024: FDA Approvals, Pipeline, - openPR
A History of Outperforming Analyst Forecasts and Beating the Odds: PDS Biotechnology Corporation (PDSB) - SETE News
Comparing Moolec Science (NASDAQ:MLEC) & Ross Acquisition Corp II (NYSE:ROSS) - Defense World
Snap-on Incorporated (NYSE:SNA) CFO Aldo John Pagliari Sells 4,473 Shares of Stock - Defense World
Samsara Inc. (NYSE:IOT) Insider John Bicket Sells 78,128 Shares of Stock - Defense World
PDS Biotechnology (NASDAQ:PDSB) Upgraded to "Strong-Buy" by Alliance Global Partners - MarketBeat
PDS Biotechnology (NASDAQ:PDSB) Given New $7.00 Price Target at Alliance Global Partners - Defense World
PDS Biotechnology (NASDAQ:PDSB) Price Target Raised to $7.00 - MarketBeat
PDS Biotechnology Co. (NASDAQ:PDSB) Given Consensus Rating of "Buy" by Brokerages - MarketBeat
Western Wealth Management LLC Purchases 1,800 Shares of Ares Capital Co. (NASDAQ:ARCC) - Defense World
Recurrent or Metastatic Head and Neck Cancer Pipeline Analysis 2024: Clinical Trials, FDA, EMA, PMDA Approvals - openPR
PDS Biotechnology Co. Forecasted to Earn FY2024 Earnings of ($1.17) Per Share (NASDAQ:PDSB) - MarketBeat
Aixtron Se (OTCMKTS:AIXXF) Sees Significant Decrease in Short Interest - Defense World
Vanguard Group Inc. Has $6.23 Million Stock Position in AstroNova, Inc. (NASDAQ:ALOT) - Defense World
Vanguard Group Inc. Grows Stock Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
PDS Biotechnology Co. Forecasted to Post Q3 2024 Earnings of ($0.28) Per Share (NASDAQ:PDSB) - MarketBeat
Noble Financial Weighs in on PDS Biotechnology Co.’s Q3 2024 Earnings (NASDAQ:PDSB) - Defense World
PDS Biotechnology (NASDAQ:PDSB) Posts Earnings Results - Defense World
PDS Biotechnology updates market on new equity sales agreement By Investing.com - Investing.com Australia
PDS Biotechnology (NASDAQ:PDSB) Announces Earnings Results - MarketBeat
PDS Biotechnology updates market on new equity sales agreement - Investing.com India
PDS Biotechnology: Q2 Earnings Snapshot - Darien Times
NetScientific's PDS Biotech prepares phase 3 trial for VERSATILE-003 - Proactive Investors USA
NetScientific's PDS Biotech prepares phase 3 trial for VERSATILE-003 - Proactive Investors UK
PDS Biotechnology: Q2 Earnings Snapshot - New Haven Register
PDS Biotechnology: Q2 Earnings Snapshot - San Antonio Express-News
PDS Biotechnology updates market on new equity sales agreement - Investing.com
PDS Biotechnology: Q2 Earnings Snapshot - Houston Chronicle
PDS Biotechnology updates market on new equity sales agreement By Investing.com - Investing.com UK
PDS Biotechnology Enhances and Modulates Stock Sales Agreement - TipRanks
PDS Biotechnology: Q2 Earnings Snapshot - San Francisco Chronicle
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results - BioSpace
PDS Biotechnology: Q2 Earnings Snapshot - Press of Atlantic City
PDS Biotech: Business Update and Q2 2024 Results - ShareCast
PDS Biotechnology: Q2 Earnings Snapshot - CTPost
PDS Biotechnology: Q2 Earnings Snapshot - Greenwich Time
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results - wallstreet:online
PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results - StockTitan
Pds Biotechnology Corporation Stock (PDSB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):